Emergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
Adjusted EBITDA: Q4 2023 Adjusted EBITDA was $3.4 million, a significant drop from $44.0 million in Q4 2022. Product Sales: NARCAN sales increased by 22% in Q4 2023, while Smallpox MCM sales saw a 92% decrease. Operating Expenses: Q4 2023 total operating expenses decreased by 17% year-over-year. Capital Expenditures: Capital expenditures in Q4 2023 decreased by 52% compared to Q4 2022. Guidance: EBS issued financial guidance for Q1 2024 and the full year 2024. Warning! GuruFocus has detected 4 Warning Signs with EBS. On March 6, 2024, Emergent BioSolutions Inc ( NYSE:EBS ) released its 8-K filing , detailing the financial outcomes for the fourth quarter and full year ended December 31, 2023. The company, known for its public health products, operates mainly in two segments: Products and Services. Most of its revenue is derived from U.S. government contracts for vaccines, devices, and therapeutic products. Fiscal Summary The fourth quarter saw a 16% decline in total re
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- FDA approves Amneal's generic version of OTC Narcan [Seeking Alpha]Seeking Alpha
- Ascend Hires Scott Law as COO and Continues Strengthening Foundation [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024GlobeNewswire
- Institutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year losses [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 3/6/24 - Miss
EBS
Sec Filings
- 4/26/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- EBS's page on the SEC website